We’re excited to announce our new strategic partnership with Verily – Georgiamune Inc.
Georgiamune Inc. made the following post on LinkedIn:
“We’re excited to announce our new strategic partnership with Verily, an Alphabet precision health technology company, to advance our novel pipeline of immune therapeutics for cancer and autoimmune diseases. Verily’s state-of-the-art molecular and real-world evidence solutions will support the development of our therapeutic candidates through the discovery of predictive and outcome biomarkers. Our two companies will work together to advance innovation on how clinical trials are conducted through driving more efficient clinical development by incorporating clinical trial data and longitudinal real-world data sources.
As a first step, we will implement immune mapping with Verily’s Immune Profiler for GIM-122, our first-in-class dual-functioning antibody, to assess its pharmacodynamic effect and interrogate the immune response of patients in our current first-in-human, phase 1/2 clinical trial.
Read more about this innovative partnership on our website.”
Source: Georgiamune Inc./LinkedIn